QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
Free Trial
NYSE:AGN

Allergan (AGN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free AGN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$191.64
▼
$193.38
50-Day Range
$184.04
▼
$193.89
52-Week Range
$114.27
▼
$202.21
Volume
12.44 million shs
Average Volume
4.01 million shs
Market Capitalization
$63.50 billion
P/E Ratio
N/A
Dividend Yield
1.53%
Price Target
N/A
Stock Analysis
Stock Analysis
AGN stock logo

About Allergan Stock (NYSE:AGN)

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

AGN Stock News Headlines

April 11, 2024 | finance.yahoo.com
Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Accelerate Aesthetics Start-Ups
April 5, 2024 | uk.investing.com
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 26, 2024 | finance.yahoo.com
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
February 28, 2024 | finance.yahoo.com
Dr. Ran Y. Rubinstein Has Been Named Top 500 Allergan Aesthetic 2024
January 23, 2024 | in.investing.com
Pro Research: Wall Street eyes AbbVie's growth and pipeline potential
January 23, 2024 | finance.yahoo.com
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
January 18, 2024 | finance.yahoo.com
BodyLase® Med Spa Ends 2023 Among Top 50 Allergan Providers
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 4, 2024 | reuters.com
Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
December 29, 2023 | za.investing.com
Pro Research: Wall Street explores AbbVie's market dynamics
December 26, 2023 | za.investing.com
Pro Research: wall street dives into abbvie's growth potential
December 19, 2023 | finance.yahoo.com
Dr. Ran Y. Rubinstein: Revolutionizing Aesthetics for 18 Years as an Expert Allergan and Galderma Trainer
October 24, 2023 | markets.businessinsider.com
Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines
October 19, 2023 | finance.yahoo.com
Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
October 18, 2023 | finance.yahoo.com
Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Ups
October 10, 2023 | msn.com
Unlocking Vision Wellness: Allergan’s Media Conclave On World Sight Day Spotlights Eyecare's Crucial Role In Modern Workplace
September 15, 2023 | thestreet.com
Allergan (AGN), Pfizer in Advanced Takeover Talks, Stocks Fall, Jim Cramer Weighs In
August 2, 2023 | ca.investing.com
Bausch + Lomb's Saunders doesn't expect more big deals in the near term
August 2, 2023 | za.investing.com
Bausch + Lomb posts better than expected Q2 earnings
August 1, 2023 | finance.yahoo.com
Allergan Aesthetics Announces First Ever JUVÉDERM® Day
July 24, 2023 | thestreet.com
Why Valeant Pharmaceuticals (VRX) Stock Is Up
July 7, 2023 | thestreet.com
Cramer -- Why a Pfizer Merger With Allergan Makes Sense
June 9, 2023 | msn.com
N.C. to receive $521M in opioid settlements with Teva, Allergan, CVS and Walgreens
June 9, 2023 | msn.com
Virginia receives $365.6 million in opioid settlements with Teva, Allergan, CVS, and Walgreens
May 22, 2023 | thestreet.com
Pfizer (PFE) Stock Sinks, Negotiating Break-Up Fee in Allergan Deal, Jim Cramer's View
May 17, 2023 | marketwatch.com
Bipolar Disorder Therapeutics Market Size, Growth Opportunities, Future Trends and Share with Revenue Forecast 2028
See More Headlines
Receive AGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/10/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:AGN
Previous Symbol
NYSE:ACT
CUSIP
01849010
CIK
1578845
Web
www.allergan.com
Phone
862-261-7000
Fax
N/A
Employees
17,400
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$17.64
Trailing P/E Ratio
N/A
Forward P/E Ratio
11.56
P/E Growth
1.63
Net Income
$-5,271,000,000.00
Net Margins
-15.44%
Pretax Margin
N/A
Return on Equity
8.46%
Return on Assets
5.31%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.01
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$16.09 billion
Price / Sales
3.95
Cash Flow
$36.70 per share
Price / Cash Flow
5.26
Book Value
$177.28 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
329,002,000
Free Float
N/A
Market Cap
$63.50 billion
Optionable
Optionable
Beta
1.20
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

Should I Buy Allergan Stock? AGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Allergan plc:

  • Allergan plc is a well-established pharmaceutical company with a diverse portfolio of branded pharmaceuticals, devices, biologics, and surgical products.
  • Recent developments in research and development have led to the creation of innovative and potentially lucrative products.
  • The company has a strong track record of successful mergers and acquisitions, which could lead to further growth and expansion.
  • Investors may find the current stock price of Allergan plc to be attractive for potential gains in the future.
  • Allergan plc has a global presence, providing opportunities for revenue growth in various markets.

Cons

Investors should be bearish about investing in Allergan plc for these reasons:

  • While the company has a diverse portfolio, it also means that there is increased competition in the pharmaceutical industry.
  • Regulatory challenges and changes in healthcare policies could impact the company's profitability and operations.
  • Fluctuations in currency exchange rates may affect Allergan plc's financial performance, especially in international markets.
  • The pharmaceutical industry is subject to rapid technological advancements and changes, which could impact the relevance of Allergan plc's products.
  • Investors should carefully consider the risks associated with investing in a company that operates in a highly regulated and competitive industry.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Allergan pros and cons to contact@marketbeat.com.

AGN Stock Analysis - Frequently Asked Questions

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings data on Monday, February, 10th. The company reported $5.22 EPS for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a positive trailing twelve-month return on equity of 8.46% and a negative net margin of 15.44%. The business's revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $4.29 earnings per share.

Is Allergan a good dividend stock?

Allergan (NYSE:AGN) pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.53%. The dividend payout ratio is 16.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AGN will have a dividend payout ratio of 16.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AGN.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

This page (NYSE:AGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends